In experimental animals and humans, intravenous (IV) injection of endotoxin induces large increases in circulating plasminogen activator inhibitor type-l (PAI-l), a major inhibitor of blood fibrinolysis. A similar increase is seen after the injection of interleukin-l (IL-l) or of tumor necrosisfactor-a (TNFa), suggesting that these cytokines mediate the induction, by endotoxin, of PAI-1. To test this hypothesis we pretreated rats, before IV endotoxin, with compounds that inhibit the formation of cytokines (pentoxifylline; dexamethasone), or LASMINOGEN ACTIVATOR inhibitor type-1 (PAI-1) is one of the plasma factors that determine the plasminogen activating potential of blood. Thus, increased blood levels of this inhibitor are likely to reduce blood fibrinolysis and thrombolysis, making PAI-1 a potential risk factor for cardiovascular disease and thromb~embolism."~ Many types of insult will induce increased levels of plasma PAI-1 activity, examples of which are sepsis, surgery, and trauma."6 Gram-negative endotoxemia, both experimentally7.' and clinical1y?-l6 strongly increases the plasma level of PAI-1 in humans.
LASMINOGEN ACTIVATOR inhibitor type-1 (PAI-1)
is one of the plasma factors that determine the plasminogen activating potential of blood. Thus, increased blood levels of this inhibitor are likely to reduce blood fibrinolysis and thrombolysis, making PAI-1 a potential risk factor for cardiovascular disease and thromb~embolism."~ Many types of insult will induce increased levels of plasma PAI-1 activity, examples of which are sepsis, surgery, and trauma."6 Gram-negative endotoxemia, both experimentally7.' and clinical1y?-l6 strongly increases the plasma level of PAI-1 in humans.
In previous studies, we1'-'' and other^^^'^-'^ have shown that the injection of low doses of endotoxin into experimental animals will induce large and rapid increases of circulating PAI-1, due to de novo synthesis of PAI-l.24 As a corollary to these studies we have shown that the endotoxin-induced cytokines interleukin-la (IL-1a),I7 IL-1P,l9 and tumor necrosis factor-a (TNF-cY)~~ will also increase plasma PA1 activity in rats.
In combination, these observations suggested to us that the endotoxin-induced increase in PAI-1 activity might be mediated by endotoxin-induced cytokines, especially IL-1 and TNF-a. To test this hypothesis we pretreated rats either with compounds that prevent the synthesis and/or secretion of cytokines (dexamethasone, pentoxifylline) or with compounds that inhibit the effects of cytokines ( L 1 receptor antagonist for IL-1; anti-TNF antiserum for TNF-a), and measured the subsequent endotoxin-induced increase in PAI. We also measured tissue-type plasminogen activator (tPA) antigen levels in these rats, because tPA is known to be increased as well after endotoxin injection. The increase in PA1 activity was not affected by any of these treatments, whereas the increase in tPA antigen was. We propose that, contrary to our hypothesis, the endotoxin-induced cytokines IL-1 and TNF-a are not significantly involved in the induction of PAI-1 by endotoxin.
P MATERIALS AND METHODS

Materials. Endotoxin (lipopolysaccharide [LPS]
, from Escherichia coli serotype 0128:B12; Sigma, St Louis, MO) was dissolved in sterile saline to a concentration of 10 pg/mL. All other compounds were dissolved in sterile saline containing 1% (wdvol) sterile, pyrogen-free human serum albumin (Central Laboratory of the Red Cross Blood Transfusion Service, Amsterdam, The Netherlands). Recombinant human TNF-a (2.5 X lo7 U/mg protein; a gift from Dr W. Fiers, Biogent, Gent, Belgium) was diluted to 10 pg/mL. RecombiBlood, Vol 85, No 1 (January l), 1995: pp 115-120 with compounds that inhibit the action of these cytokines (anti-TNF antiserum for TNF-a; IL-l receptor antagonist for IL-l). None of these pretreatments affected the induction of PAL1 synthesis by endotoxin. However, pretreatment did reduce the endotoxin-induced increase in plasma tPA antigen concentration. Thus, the data suggest that, in rats in vivo, TNF-a and IL-l are not significantly involved in the induction of PAI-1 by endotoxin. 0 1995 by The American Society of Hematology.
nant human IL-lP (lo8 U/mg; a gift from Dr S. Gillis, Immunex, Seattle, WA) was diluted to 2 pg/mL. Recombinant mouse TNF-a, rabbit-antimouse TNF-a antiserum, and an enzyme-linked immunosorbent assay (ELISA) kit for mouse TNF-a were obtained from Genzyme (Boston, MA). Recombinant human IL-l receptor antagonist (IL-lra; a gift from Dr D.E. Tracey, The Upjohn CO, Kalamazoo, MI) was diluted to 1 mg/mL. Pentoxifylline (Trental) was from Hoechst AG (Wiesbaden, Germany), and was used as supplied (20 mg/mL). Dexamethasone (Sigma) was first dissolved in ethanol (IO mg/mL), and then diluted to 1 mg/mL in saline. Recombinant human tissue-type plasminogen activator (PA; Activase) was from Genentech (San Francisco, CA). Recombinant rat JMI-229 tPAZ6 was a gift from Dr S.D. Prior (Porton Developments Ltd. Salisbury, UK). Rabbit-antirat tPA IgG and rat Lz tPA have been described prev i o u~l y .~~ Rabbit-antirat PAI-l IgG was obtained from American Diagnostica (Greenwich, CT). Biotine, avidin-peroxidase, and tetramethylbenzidine were from Pierce (Rockford, IL).
Animal experimentation. Male Wistar rats (200 to 250 g body weight) were obtained from the Broekman Institute (Someren, The Netherlands). All experiments were performed under Nembutal anaesthesia (60 mgkg, intraperitoneally). Injections were administered into the vein of the penis. Blood was obtained by aortic puncture into precooled syringes, and anticoagulated with 0.13 m o a trisodium citrate (1 v01 to 9 v01 of blood). Platelet-poor plasma was immediately prepared at 4°C by centrifugation for 10 minutes at 2,00Og, and stored at -20°C. Serum was prepared for 30 minutes at 37°C and 30 minutes at 4"C, followed by centrifugation for 10 minutes at 2,0008.
Animal experiments had been approved by the Animal Experiments Committee of The Netherlands Organization for Applied Scientific Research TNO, and were in accordance with the guidelines on animal experimentation presented to the International Committee of Thrombosis and Haemostasis."
Experimental design. Rats were injected with a compound under study, followed-after an interval of 30 to 60 minutes, as detailed below-by the intravenous (IV) injection of LPS ( I O pgikg), recombinant human TNF-a (10 pgkg), or recombinant human IL-lp (1 pgikg). Blood for the assay of PAI-l activity was obtained 3 hours'7.'* later. To assess the effect of pretreatment on the induction of TNF-a by LPS, rats were bled 1 hour after LPS.
TNF-a assay. TNF-a concentrations were determined in serum by a cytotoxicity assay, using a subclone of the WEHI 164/13 mouse fibrosarcoma cell line as the indicator cell, essentially as described by Espevik and Nissen-Meyer." The assay was calibrated using recombinant mouse TNF-a, and had a lower limit of sensitivity of l pg/mL. Rat serum samples were assayed at dilutions of l:lO, SO, 250, and 1,250. In the serum samples TNF-a was specifically detected at levels 250 pg/mL. PA1 assay. Plasma PA1 concentrations were determined in appropriately diluted plasma by titration with human recombinant tPA (Activase), followed by determination of the residual tPA activity, as described by Verheijen et al."' Results will be expressed as units (U) per milliliter, 1 U/mL being equivalent to 1 ng of tPA inhibited per mL of plasma.
tPA antigen assay. Rat tPA antigen was determined by an ELISA, as follows. Microtiter plates were coated with rabbit-antirat tPA IgGZ7 (4 pg/mL in carbonate buffer, pH = 9.0) overnight at 4°C and washed. Samples (diluted in phosphate-buffered saline [PBS] containing 5 mg/mL casein) were incubated overnight at 4°C and washed. Bound tPA was subsequently quantitated using biotinylated rabbit-antirat tPA IgG, followed by avidin-peroxidase and tetramethylbenzidine. Rat tPA purified from Lz cells (0.5 to 4.0 ng/mL) was used as standard. The rat Lz tPA had been calibrated against recombinant rat JMI-229 tPA.2b Results will be expressed as nanograms of rat tPA per milliliter.
Statistics. Statistical significance of differences between groups will be analysed by Student's t-test, or by one-way ANOVA followed by Bonferroni's modified t-test, as indicated. Differences will be considered significant if P (two-sided) < .OS.
RESULTS
Effect of pentoxihlline and dexamethasone on TNF-a induction. A pilot experiment (not shown) demonstrated that peak TNF-a levels were found 1 hour after the injection of LPS at a dose of 10 pgkg. No TNF-a was detectable in saline-injected controls. Pretreatment of rats with pentoxifylline (50 m g k g IV 1 hour before LPS), or with dexamethasone (2 m g k g intraperitoneally 2 hours before LPS), significantly reduced serum TNF-a levels (measured I hour after LPS) from a mean value of 20,500 pg/mL in salinepretreated rats to 770 pg/mL (4% of controls) in pentoxifylline-pretreated rats, and to 339 pg/mL (2% of controls) in dexamethasone-pretreated rats ( Table  1 ) . At 3 hours after LPS, mean (n = 3) serum TNF-a values were 132 pg/mL in saline-pretreated rats and 133 pg/mL in pentoxifyllinepretreated rats, whereas no TNF-a was detected in dexamethasone-pretreated animals. Closely similar values were found when TNF-a levels were determined by ELISA, using an ELISA kit for mouse TNF-a which also measures rat TNF-a (data not shown).
Effect oj' LPS on plasma PAI activity. LPS ( 10 ,ug/kg) induced, as we described p r e~i o u s l y , '~~~" a large increase in plasma PA1 activity. In the present study, the plasma PA1 activity averaged, in all saline-pretreated animals combined, 12 1 U/mL at 3 hours after LPS injection, representing a 25-fold increase over the baseline level of 4 to 6 U/mL. The identification of the increased inhibitory activity as PAI-I activity has been described,'"24 and could in the present study be confirmed by quenching the LPS-induced activity by rabbit-antirat PAI-l IgG (not shown).
Effect ofpentoxihlline and dexamethasone on PAI induction b y LPS. Pretreatment with pentoxifylline
(20, 50, or 100 mg/kg IV, 1 hour before LPS) had no effect on the induction of PA1 by LPS. Saline-pretreated animals had PA1 levels of 134 5 33 U/mL (mean +-SD; n = 9); pentoxifylline-pretreated rats had PA1 levels of I18 2 I8 U/mL for pentoxifylline at 20 mg/kg (n = 5); 123 +-13 U/mL for pentoxifylline at 50 mg/kg (n = 4); and 1 1 I 2 21 U/mL for pentoxifylline at 100 mg/kg (n = 4). These differences were not significant by one-way ANOVA. Injection of only pentoxifylline did not affect plasma PA1 activity, as we described previously.3' Acute pretreatment with dexamethasone (2 mg/kg intraperitoneally 2 hours before LPS) had no effect on the induction of PA1 by LPS (Table 2) , nor did subchronic pretreatment with dexamethasone ( 2 mg/kg intraperitoneally, once daily for 4 days) ( Table 2) . Corticosterone had no effect either (Table 2) . Dexamethasone alone (without LPS) increased PA1 activity about twofold.24 For No significant differences were present between groups 1-5 by oneway ANOVA. Group 6 was significantly different from group 7a. and group 8 from group 9a. by Student's t-test. Rats were pretreated with anti-TNF antiserum (0.1 or 0.3 murat), with control rabbit serum (0.1 murat), with IL-Ira (1 or 4 mg/kg), or with saline, followed by either LPS (10 pg/kg), recombinant human TNF-a (10 pg/kg), or recombinant human IL-1/3 (1 pgikg). Rats were killed 3 hours after LPS, TNF or IL-1. For further details, see Materials and Methods.
Effect of anti-TNF antiserum, IL-I receptor antagonist (IL-Ira), or both, on PAI induction by LPS. Pretreatment of rats with an antimouse-TNF antiserum (0.1 mL/rat) had no significant effect on the induction of PA1 by LPS, compared to pretreatment with control rabbit serum (Table 3 ). Higher doses of the antiserum (0.15 or 0.3 mUrat, n = 2 per dose) had no effect either ( Table 3 ). The anti-TNF antiserum did reduce, though, the induction of PA1 activity by recombinant human TNF-a, inhibiting partially at a dose of 0.1 mL/rat and fully at a dose of 0.3 mL/rat (Table 3) . At a dose of 1 mgkg, recombinant human IL-lra significantly inhibited the induction of PAI-l activity by recombinant human IL-Ip (1 & k g ) , whereas at a dose of 4 mgkg the receptor antagonist fully inhibited the induction by IL-1p ( Table 3) . In contrast, IL-lra did not affect the induction of PA1 by LPS at all (Table 3) . Combined pretreatment with anti-TNF and IL-lra had no effect on the induction of PA1 by LPS either (Table 3) .
Additive effects of TNF-a and IL-IP. To see whether residual circulating levels of one cytokine would potentiate the other, rats (two per group) were injected with TNF-a (10 & k g ) with or without simultaneous injection of a small dose of IL-lp (0.1 pgkg), or with only IL-1p (0.1 Fgkg). No potentiating effect on PA1 induction was observed: TNFa alone gave PA1 activities of 18 and 20 U/mL; IL-1p alone 8 and 11 U/mL; TNF-a plus IL-lp 19 and 20 U/&. Sirnilarly, no potentiation of IL-lp (1 & k g ) by a small dose of TNF-a (1 pgkg) was seen: IL-1p alone gave PA1 activities of 25 and 25 U/mL; TNF-a alone 12 and 13 U/mL; IL-lp (10 & k g ) gave 35 and 42 U/mL. These data suggest that the combined effect of IL-1p and TNF-a is additive rather than synergistic. This makes it unlikely that residual amounts of TNF-a activity [remaining after anti-TNF treatment) would potentiate IL-lp, or that residual L -l p activity (after IL-lra treatment) would potentiate TNF-a. The effect of TNF-a on PAI-1 was linearly related to the injected dose of TNF-a over the dose-range 0.5 to 60 ,&kg (n = 9; r = .895; P < .01).
Changes in tPA antigen concentrations. LPS induced a time-dependent increase in tPA antigen (Fig l) , preceding the induction of PA1 which commences only after 1 hour." Increases in tPA antigen of a magnitude similar to that induced by LPS were found at 3 hours after the injection of IL-1p and TNF-a ( Table 4) . The tPA increase after LPS was partly inhibited by pentoxifylline, dexamethasone, anti-TNF antiserum, and IL-l-ra (Table 4) . Similarly, anti-TNF antiserum and IL-l-ra partly inhibited the tPA increase induced by, respectively, TNF-a and IL-lp ( Table 4) . Inhibition was not complete, presumably because the high PA1 levels in the circulation caused the formation of more tPA-PA1 complexes, which are cleared from the circulation more slowly than uncomplexed tPA.32 plus TNF-a 30 and 38 U/mL. IL-lp (1 & k g ) plus TNF-a
DISCUSSION
This study was designed to test the hypothesis that the induction of PAI-l by endotoxin is mediated by the cytokines TNF-a and/or IL-1. This hypothesis originated from two sets of observations. Firstly, the observation that endotoxin, a potent inducer of PAI-1, is also a potent inducer in vivo of IL-1 and TNF-a. Secondly, the observation that both cytokines will increase PAL1 in vivo. IL-la and p have been shown to induce PAL1 in rats,"*19 whereas TNF-a For 
3
All data shown are mean 2 SD. Groups 2-7 were not significantly different by one-way ANOVA. When groups 2 and 3 and groups 4-7 were combined, the two new groups (non-pretreated v pretreated)
were significantly different by Student's t-test (P < .01). Group 8 was significantly different from group 9, and group 10 from group 11, by Student's t-test ( P < .05). Rats were pretreated with saline, control rabbit serum (0.1 murat), pentoxifylline (50 mg/kg IV), dexamethasone (2 mg/kg intraperitoneally), anti-TNF antiserum (0.1 murat), or IL-Ira (1 mg/kg), followed by either LPS (10 pg/kg), recombinant human TNF-(U (10 pg/kg), or recombinant human IL-ID (1 pg/kg). Rats were killed 3 hours after LPS, TNF, or IL-l. For further details, see Materials and Methods.
has been shown to induce PAI-I in mice,'? rat^,'"^^^'^ and humans.35-3K However, the present study provided no support for our hypothesis: all four procedures meant to interfere with the production and/or action of cytokines (pretreatment with pentoxifylline, dexamethasone, anti-TNF antiserum, or IL-I receptor antagonist) all failed to reduce the induction of PAL1 by endotoxin. Pentoxifylline inhibits the induction, by endotoxin, of TNF-a synthesis by inhibiting the transcription of TNF-a mRNA." It is effective in all species tested, including humans:' ~h i m p a n z e e ,~"~' and rat. 43 In this study, it inhibited the induction of TNF-a by 96% (Table l) , but failed to affect the induction of PAI-I by endotoxin. Dexamethasone, which inhibits the translation of TNF-a mRNA? also inhibited the induction of TNF-a (by 98%, Table l), in agreement with a study in rats which used a similar dosage regimen?' But, like pentoxifylline, dexamethasone had no effect on PA1 induction ( Table 2) . In addition, an antimurine-TNF antiserum that also inhibits rat TNF-a had no effect on PA1 induction, though it fully inhibited the induction of PA1 by (human) TNF-a (Table 3) . All in all, these data showed that blocking the synthesis (pentoxifylline, dexamethasone), or the effect (anti-TNF antiserum) of TNF-a did not affect the induction of increased PAI-1 synthesis by endotoxin. albeit more slowly, peak levels being obtained only at 5 hours after endotoxin ie, after the peak level of PAL1 has been reached (at 3 to 4 hours"). Dexamethasone also inhibits, as for TNF-a, the induction of IL-1 activity4' and of IL-l mRNA,4* via effects on translation and secret i~n .~' Pentoxifylline is not known to reduce the induction Similar to TNF-a, IL-lP is induced in rats by of IL-I .") To block the effects of IL-I, we used an IL-1 receptor antagonists'.52 that effectively inhibits IL-I -induced effects in a variety of species,s3 including However, like dexamethasone, IL-1 ra had no effect on PAI-1 induction by endotoxin in this study, though it inhibited the induction of PA1 by human IL-lP (Table 3) .
Endotoxin not only induces increased plasma levels of PAI-I, but also of tPA, induction of tPA preceding that of PAI-1, as has been observed both in and in chimpanzees." Increased tPA antigen levels have also been described in humans after treatment with TNF-cx."-'~ In the present study similar increases were noted after treatment of rats with endotoxin (Fig l ) , TNF-a, and IL-I@ (Table 4) , an observation not made in rats before. The increase in tPA antigen after the injection of TNF-a was reduced by anti-TNF antiserum, and the increase after IL-I@ by IL-Ira ( Table   4 ). The increase in tPA antigen after endotoxin injection was reduced, though to a lesser extent, by pretreatment with pentoxifylline, dexamethasone, anti-TNF antiserum, and ILIra. This suggests that pretreatment with anti-TNF antiserum and IL-Ira was not only effective against injected (human) TNF-a or IL-l@, but also against endogenous TNF-a and IL-I . That tPA was not reduced to normal control levels is presumably due to the fact, mentioned above, that the induction of PAI-1 still occurred in all animals, resulting in increased circulating levels of tPA-PA1 complexes that are detected by our tPA ELISA assay. Also, it is likely that tPA release is induced" after endotoxin injection by other endotoxin-induced compounds such as platelet-activating factor, catecholamines, vasopressin, etc.
Because synergistic effects between TNF-a and IL-1 have been reported (eg, ref 56), and because in our experiments low residual levels of cytokines activity are likely to be present during treatment with antiserum or with receptor antagonist, we investigated whether synergistic effects on PA1 synthesis could be detected. As described above, no such synergy between TNF-a and IL-10 was found, using various combinations of the two cytokines, but rather additive effects. Moreover, because the PA1 response to TNF-a was linear over the TNF concentration range 0.5 to 60 ,ug/ kg, we consider it unlikely that residual amounts of TNF (or IL-I) would significantly have affected the PA1 concentrations.
In a previous publicationz4 we have shown that a variety of autacoids that are induced or released by endotoxin in vivo (eg, cyclo-oxygenase and lipoxygenase products, plateletactivating factor, catecholamines, histamine, cyclic nucleotides, opioids, vasopressin, thrombin) are not involved in the induction of PAI-I by endotoxin. It has also been shown that IL-6 is unable to induce PAL1 in rats in v~vo,'~,'' as is the case in vitro.25,'X Our present observations suggest that IL-1 and TNF-a do not mediate the effect of endotoxin on PAI-l either. Thus, the mechanism by which endotoxin induces increased synthesis of PAL1 in vivo remains unexplained. This situation is the more unfortunate because it was recently suggested2' that TNF-a mediates, in chimpanzees, the endotoxin-induced increase in tPA that precedes the increase in PAL1 activity, an observation in agreement with our data. It follows that inhibiting TNF-a will, at least For personal use only. on September 14, 2017. by guest www.bloodjournal.org From LPS, PAI-1, AND CMOKINES 119 in rats, inhibit the profibrinolytic, tPA-mediated, effect of endotoxin without interfering with its antifibrinolytic, PAI-1 -mediated effect. In combination, these effects might then shift the fibrinolytic balance in blood even further to an inhibitory state, worsening the procoagulant effects of endotoxin. It would be of interest to study whether this situation, as described here for rats, also applies to primates and humans.
